Enterprise Value

-49.41M

Cash

112M

Avg Qtr Burn

-14.17M

Short % of Float

3.57%

Insider Ownership

0.54%

Institutional Own.

39.34%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Voruciclib (CDK Inhibitor) Details
B-cell malignancies, Acute myeloid leukemia, Cancer

Phase 1b

Data readout

Phase 1b

Initiation

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued